New pill shows promise for Hard-to-Treat blood cancers
NCT ID NCT03913949
First seen May 03, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This early-phase study tests an oral drug called APG-2575 in adults with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to find a safe dose and check for side effects. About 74 participants will take the drug by mouth, and researchers will measure how the body processes it. This is not a cure; it aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anhui Procincial hospital
Hefei, Anhui, China
-
Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Henan Provincial Oncology Hospital
Zhengzhou, Henan, China
-
The First Affiliated Hospital, Zhejiang University School of Medicin
Hangzhou, Zhejiang, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.